15,000
Participants
Start Date
January 18, 2024
Primary Completion Date
December 30, 2025
Study Completion Date
March 1, 2026
Signal-C™
Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
RECRUITING
Blue Ridge Medical Research, Lynchburg
Lead Sponsor
Collaborators (2)
Premier Research Group plc
UNKNOWN
Yanuvia, LLC
UNKNOWN
Science 37
INDUSTRY
Universal Diagnostics
INDUSTRY